Malignant Neoplasm of Uterine Adnexa, Unspecified (C57.4)

Name of the Condition

• Common name: Uterine Adnexa Cancer (Unspecified)
• Technical term: Malignant neoplasm of uterine adnexa, unspecified

Summary

This condition refers to a cancerous growth originating in the uterine adnexa, which includes structures such as the fallopian tubes, ovaries, and supporting ligaments. The term "unspecified" indicates the exact site within the adnexa may not be clearly identified at diagnosis, requiring further evaluation to determine the precise location and nature of the neoplasm. Uterine adnexa malignancies are part of the broader category of female genital cancers and can involve uncontrolled cell growth with potential to invade nearby tissues or spread.

Causes

The exact causes vary depending on the specific structure involved. Genetic mutations, hormonal influences, and environmental factors may contribute to the development of these cancers. Infections, such as certain strains of HPV, and chronic inflammatory conditions can also play a role in some cases. The "unspecified" nature of the code may reflect incomplete diagnostic information at the time of coding.

Risk Factors

• Advanced age
• Family history of gynecological cancers
• Genetic predispositions (e.g., BRCA mutations)
• Hormonal imbalances or therapies
• Prior pelvic conditions or surgeries
• Chronic inflammatory diseases

Symptoms

Typical symptoms may include:

• Abnormal vaginal bleeding or discharge
• Pelvic pain or pressure
• Abdominal swelling or bloating
• Unexplained weight loss
• Urinary or bowel habit changes
• Palpable pelvic mass

Diagnosis

Diagnosis involves a combination of pelvic examination, imaging tests (e.g., ultrasound, CT, or MRI) to identify masses, and biopsy of suspicious tissue. Blood tests for tumor markers (e.g., CA-125) may also be used to support diagnosis. The "unspecified" designation may apply if the exact adnexal structure is not confirmed during initial evaluation.

Treatment Options

Treatment depends on the specific site, stage, and patient factors. Options may include:

• Surgery to remove the affected adnexal structure(s)
• Chemotherapy or radiation therapy
• Hormonal therapies
• Targeted therapies for specific genetic mutations

Prognosis and Follow-Up

Prognosis varies based on the specific site, stage at diagnosis, and response to treatment. Regular follow-up with imaging and clinical evaluations is typically recommended to monitor for recurrence. Long-term outcomes depend on factors like tumor grade, spread, and treatment effectiveness.

Complications

Potential complications include:

• Metastasis to other pelvic or distant organs
• Bowel or urinary obstruction
• Infection or bleeding from treatment
• Hormonal imbalances affecting reproductive function

Lifestyle & Prevention

• Maintain a healthy weight and balanced diet
• Avoid smoking and limit alcohol
• Practice safe sex to reduce HPV risk
• Discuss family history with a healthcare provider for genetic counseling
• Attend regular gynecological screenings

When to Seek Professional Help

Seek medical attention for persistent pelvic pain, abnormal bleeding, unexplained weight loss, or abdominal swelling. Early evaluation is critical for timely diagnosis and treatment.

Tips for Medical Coders

When coding C57.4, ensure documentation supports the "unspecified" nature of the uterine adnexa malignancy. Verify that the site is not further specified (e.g., fallopian tube or ovary) in the record. If additional details emerge later, update the code to the most specific available category. Document the rationale for using "unspecified" if the exact adnexal structure cannot be determined from clinical findings.